Kolahchi Zahra, Rahimian Nasrin, Momtazmanesh Sara, Hamidianjahromi Anahid, Shahjouei Shima, Mowla Ashkan
School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Department of Neurology, Creighton University Medical Center, Omaha, NE 68124, USA.
Life (Basel). 2023 Jan 9;13(1):185. doi: 10.3390/life13010185.
The current guideline recommends using an intravenous tissue-type plasminogen activator (IV tPA) prior to mechanical thrombectomy (MT) in eligible acute ischemic stroke (AIS) with emergent large vessel occlusion (ELVO). Some recent studies found no significant differences in the long-term functional outcomes between bridging therapy (BT, i.e., IV tPA prior to MT) and direct MT (dMT).
We conducted a systematic review and meta-analysis to compare the safety and functional outcomes between BT and dMT in AIS patients with ELVO who were eligible for IV tPA administration. Based on the ELVO location, patients were categorized as the anterior group (occlusion of the anterior circulation), or the combined group (occlusion of the anterior and/or posterior circulation). A subgroup analysis was performed based on the study type, i.e., RCT and non-RCT.
Thirteen studies (3985 patients) matched the eligibility criteria. Comparing the BT and dMT groups, no significant differences in terms of mortality and good functional outcome were observed at 90 days. Symptomatic intracranial hemorrhagic (sICH) events were more frequent in BT patients in the combined group (OR = 0.73, = 0.02); this result remained significant only in the non-RCT subgroup (OR = 0.67, = 0.03). The RCT subgroup had a significantly higher rate of successful revascularization in BT patients (OR = 0.73, = 0.02).
Our meta-analysis uncovered no significant differences in functional outcome and mortality rate at 90 days between dMT and BT in patients with AIS who had ELVO. Although BT performed better in terms of successful recanalization rate, there is a risk of increased sICH rate in this group.
当前指南推荐在符合条件的伴有急性大血管闭塞(ELVO)的急性缺血性卒中(AIS)患者进行机械取栓(MT)之前使用静脉注射组织型纤溶酶原激活剂(IV tPA)。最近一些研究发现桥接治疗(BT,即在MT之前使用IV tPA)和直接MT(dMT)之间的长期功能结局无显著差异。
我们进行了一项系统评价和荟萃分析,以比较符合IV tPA给药条件的伴有ELVO的AIS患者中BT和dMT的安全性和功能结局。根据ELVO的位置,患者被分为前循环组(前循环闭塞)或联合组(前循环和/或后循环闭塞)。基于研究类型(即随机对照试验和非随机对照试验)进行亚组分析。
13项研究(3985例患者)符合纳入标准。比较BT组和dMT组,90天时在死亡率和良好功能结局方面未观察到显著差异。联合组中BT患者的症状性颅内出血(sICH)事件更频繁(比值比=0.73,P=0.02);该结果仅在非随机对照试验亚组中仍具有显著性(比值比=0.67,P=0.03)。随机对照试验亚组中BT患者的成功再灌注率显著更高(比值比=0.73,P=0.02)。
我们的荟萃分析发现,伴有ELVO的AIS患者中dMT和BT在90天时的功能结局和死亡率无显著差异。尽管BT在成功再通率方面表现更好,但该组存在sICH率增加的风险。